Entacapon ( DrugBank: - )

1 disease

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	95

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

diseases per page:

Showing 1 to 10 of 95 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2051200104	06/01/2021	24/12/2020	A Phase 1 Study of KK6483 in Healthy Male Volunteers	A Phase 1 Study of KK6483 in Healthy Male Volunteers	Parkinson's disease	A single oral administration of the investigational product, KK6483C in combination with the existin ...	Yagi Michio	NULL	Complete	>= 20age old	< 45age old	Male	40	Phase 1	Japan
2	ChiCTR2000039050	2020-10-30	2020-10-14	Efficacy of levodopa/carbidopa/entacapone in the replacement of Levodopa /dopa decarboxylase inhibit ...	Efficacy of levodopa/carbidopa/entacapone in the replacement of Levodopa /dopa decarboxylase inhibit ...	Parkinson's Disease	Group 1:adding pramipexole;Group 2:adding LCE;	The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)	NULL	Pending	30	80	Both	Group 1:175;Group 2:175;	Phase 4	China
3	NCT04246437 (ClinicalTrials.gov)	February 4, 2020	25/1/2020	[18F]F-DOPA Imaging in Patients With Autonomic Failure	[18F]F-DOPA Imaging in Patients With Autonomic Failure	Autonomic Failure;Pure Autonomic Failure;Parkinson Disease;Multiple System Atrophy;Dementia With Lew ...	Drug: [18F]FDOPA;Drug: Carbidopa 200mg oral dose;Drug: Entacapone 400mg oral dose	Daniel Claassen	NULL	Recruiting	18 Years	N/A	All	40	Phase 1	United States
4	JPRN-UMIN000037390	2019/07/01	16/07/2019	An exploratory study to optimize the administration of COMT inhibitor on LCIG therapy	An exploratory study to optimize the administration of COMT inhibitor on LCIG therapy - Levodopa pha ...	Parkinson's disease	Entacapone 100mg	Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine	Saiseikai Matsuyama Hospital	Pending	20years-old	Not applicable	Male and Female	10	Not selected	Japan
5	ChiCTR1900022534	2019-06-01	2019-04-15	Efficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective ...	Efficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective ...	non-motor symptoms of Parkinson’s disease	entacapone group:Patients in the entacapone group will be administered entacapone (Novartis; import ...	Geriatric Hospital of Hainan	NULL	Pending	40	75	Both	entacapone group:194;pramipexole group:194;	N/A	China
6	NCT02554734 (ClinicalTrials.gov)	August 2015	10/6/2015	Pharmacokinetic Study in Healthy Volunteers	Pharmacokinetics of Levodopa After Repeated Doses of Carbidopa, ODM-104 and Levodopa: an Open, Rando ...	Parkinson's Disease	Drug: levodopa, carbidopa, ODM-104;Drug: levodopa, carbidopa, entacapone	Orion Corporation, Orion Pharma	NULL	Completed	18 Years	65 Years	Both	15	Phase 1	Finland
7	NCT02448914 (ClinicalTrials.gov)	May 2015	12/5/2015	A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infus ...	A Single Centre, Two-period, Open Label, Randomised, Cross-over Study to Assess Plasma Levodopa, Car ...	Parkinson's Disease	Drug: TRIGEL;Drug: Duodopa	LobSor Pharmaceuticals AB	TFS Trial Form Support	Completed	30 Years	N/A	All	11	Phase 1	Sweden
8	NCT02452606 (ClinicalTrials.gov)	March 2015	14/5/2015	Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on ...	Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on ...	Parkinson Disease;Sleep Disorders	Drug: Stalevo®	Asan Medical Center	NULL	Recruiting	20 Years	79 Years	Both	100	N/A	Korea, Republic of
9	NCT02170376 (ClinicalTrials.gov)	September 2011	19/6/2014	The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics	The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics When Administered With Imm ...	Parkinson's Disease (PD)	Drug: BIA 9-1067;Drug: Entacapone;Drug: Placebo;Drug: Levodopa/carbidopa	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	All	80	Phase 1	France
10	EUCTR2010-021860-13-BG (EUCTR)	04/08/2011	02/06/2011	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENO ...	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENO ...	Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose ...	Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive nam ...	BIAL - Portela & Ca, S.A.	NULL	Not Recruiting			Female: yes Male: yes	550		Portugal;Serbia;Slovakia;Spain;Ukraine;Lithuania;Austria;Russian Federation;Montenegro;Italy;France; ...

First Previous1 2 3 4 5…10Next Last